Document is current
Any future updates will be listed below
-
Authors
Koch, Claudia
Kuske, Andra
Joosse, Simon A https://orcid.org/0000-0002-4296-5615
Yigit, Gökhan
Sflomos, George https://orcid.org/0000-0003-2972-0549
Thaler, Sonja
Smit, Daniel J https://orcid.org/0000-0002-3190-9511
Werner, Stefan
Borgmann, Kerstin
Gärtner, Sebastian
Mossahebi Mohammadi, Parinaz
Battista, Laura
Cayrefourcq, Laure
Altmüller, Janine
Salinas‐Riester, Gabriela
Raithatha, Kaamini
Zibat, Arne
Goy, Yvonne
Ott, Leonie
Bartkowiak, Kai
Tan, Tuan Zea https://orcid.org/0000-0001-6624-1593
Zhou, Qing https://orcid.org/0000-0001-7737-9643
Speicher, Michael R https://orcid.org/0000-0003-0105-955X
Müller, Volkmar
Gorges, Tobias M
Jücker, Manfred
Thiery, Jean‐Paul https://orcid.org/0000-0003-0478-5020
Brisken, Cathrin
Riethdorf, Sabine https://orcid.org/0000-0003-0028-5643
Alix‐Panabières, Catherine https://orcid.org/0000-0002-6401-2903
Pantel, Klaus https://orcid.org/0000-0001-5736-2772
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (115749-CANCER-ID)
Deutsche Krebshilfe (70112504)
European Research Council Advanced Investigator Grant (834974)
Swiss Cancer League (KFS-3701-08-2015)
ISREC Fondation Recherche Cancer
Fondation Biltema
Deutsche Forschungsgemeinschaft (SPP2084 μBone)
Deutsche Forschungsgemeinschaft (TH 1523/3‐1)
- License Information
-
More Information
Article History
Received: 16 December 2019
Revised: 15 June 2020
Accepted: 17 June 2020
First Online: 15 July 2020
Conflict of interest
: KP and CAP have ongoing patent applications related to CTCs. KP has received honoraria from Agena, Novartis, Roche, and Sanofi and research funding from European Federation of Pharmaceutical Industries and Associations (EFPIA) partners (Angle, Menarini and Servier) of the CANCER‐ID program of the European Union–EFPIA Innovative Medicines Initiative. CAP has received honoraria from Janssen and grant support from Menarini. The remaining authors declare no conflict of interest.
